Company Monitoring Page for Novartis

latest headlines for company on cafepharma

Novartis' Kisqali sharpens survival edge with second ph3 win
Fierce Pharma
Thu, 08/1/19 - 12:00 am
Tags:
Novartis, Kisqali, breast cancer, clinical trials
Novartis' $18.5B in M&A under Vas Narasimhan says a lot about their careful — but opportunistic — deal strategy
Endpoints
Wed, 07/31/19 - 10:24 am
Tags:
Novartis, Vas Narasimhan, M&A, Pharma CEOs
Expensive Gilead, Novartis cancer therapies losing patients to experimental treatments
Yahoo/Reuters
Tue, 07/30/19 - 07:51 am
Tags:
lymphoma, Gilead Siences, Novartis, cell therapies, Kymriah, Yescarta
Novartis’ Zolgensma Joins Growing List of Medicines to Lose Accelerated Assessment Status in EU
RAPS.org
Mon, 07/29/19 - 11:19 pm
Tags:
Novartis, Zolgensma, CHMP, Europe, SMA
Novartis heart drug fails trial, curbing growth prospects
Yahoo/Reuters
Mon, 07/29/19 - 09:26 am
Tags:
Novartis, heart failure, Entresto, clinical trials
Sandoz recruits first patient in clinical study for proposed biosimilar denosumab in osteoporosis
Pharmaceutical Business Review
Tue, 07/23/19 - 10:03 am
Tags:
Novartis, Sandoz, biosimilars, clinical trials, denosumab, osteoporosis, Prolia, Xgeva
24 insurers have policies on coverage of world's most expensive drug
Beckers Hospital Review
Mon, 07/22/19 - 08:13 pm
Tags:
Novartis, payers, insurance, Medicaid, SMA, drug pricing, Zolgensma
Novartis multiple sclerosis product Gilenya approved in China
Pharmaceutical Business Review
Mon, 07/22/19 - 09:45 am
Tags:
China, Novartis, multiple sclerosis, Gilenya
8 More Big Pharma Events in 2019 You Don't Want to Miss
Motley Fool
Mon, 07/22/19 - 09:44 am
Tags:
Novartis, Pfizer, AbbVie, Bristol-Myers Squibb, Merck, GSK
Novartis licenses out early antiviral work to Gilead
Fierce Biotech
Fri, 07/19/19 - 10:51 am
Tags:
Gilead Sciences, Novartis, antivirals
Novartis’ sunny Sandoz forecast is at odds with the reality of the US generics market: analysts
Fierce Pharma
Fri, 07/19/19 - 10:47 am
Tags:
Novartis, generics, Sandoz
Payers, patients coming on board for Novartis’ Zolgensma
BioCentury
Thu, 07/18/19 - 05:58 pm
Tags:
Novartis, Zolgensma, SMA, gene therapy, payers, patients
Novartis, aiming to clean up its rep, sets aside $700M for kickback settlement
Fierce Pharma
Thu, 07/18/19 - 11:41 am
Tags:
Novartis, kickbacks
Novartis Earnings Top; Swiss Drug Giant Soars
Investors Business Daily
Thu, 07/18/19 - 10:10 am
Tags:
Novartis, earnings
Novartis secures speedy review for sickle cell drug
Biopharma Dive
Tue, 07/16/19 - 12:05 pm
Tags:
Novartis, sickle cell disease, FDA, crizanlizumab
Gilead and Novartis Seek to Expand What FDA Considers as Real-World Data and Real-World Evidence
RAPS.org
Mon, 07/15/19 - 07:06 pm
Tags:
FDA, Gilead Sciences, Novartis, RWE, real world data, real world evidence
Novartis trims again with $390m drugs sale to Recordati
Pharmaforum
Mon, 07/15/19 - 09:55 am
Tags:
Novartis, Recordati, osilodrostat, Signifor, Signifor LAR
Emgality-maker Lilly courts payers with new migraine ER data
Fierce Pharma
Fri, 07/12/19 - 12:22 pm
Tags:
Eli Lilly, Emgality, cluster headache, migraines, Amgen, Novartis, Teva Pharmaceutical, ER
Amgen, Novartis BACE Inhibitor Joins List of Failed Alzheimer’s Drugs
Xconomy
Thu, 07/11/19 - 11:15 pm
Tags:
Alzheimer's disease, BACE inhibitors, Merck, Eli Lilly, AstraZeneca, Amgen, Novartis, Biogen Eisai
Mirati and Novartis Pair Up to Evaluate Drug Combinations to Target KRAS G12C Mutations
BioSpace
Thu, 07/11/19 - 09:52 am
Tags:
Mirati Therapeutics, Novartis, KRAS, solid tumors

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.